Skip to main content
. Author manuscript; available in PMC: 2022 Jan 20.
Published in final edited form as: Semin Liver Dis. 2021 Jan 20;41(1):28–41. doi: 10.1055/s-0040-1722645

Fig. 3.

Fig. 3

Overview of various signaling pathways deregulated in human hepatoblastoma that might be therapeutically targeted. Only drugs either approved by the Food and Drug Administration or currently in clinical trials are shown. Details are reported in the main text. Stars attached to proteins indicate protein activation; blunted red arrows indicate inhibition.